

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

1. - 24. (Canceled)

25. (Previously Presented) An isolated recombinant polypeptide comprising the amino acid sequence SEQ ID NO:2.

26.- 28. (Canceled)

29. (Currently amended) An isolated recombinant polypeptide comprising an immunogenic fragment of 15 or more contiguous amino acids of SEQ ID NO:2; wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include a co-protein carrier coupled to the polypeptide or an adjuvant, is capable of inducing an antibody that specifically binds to said fragment within SEQ ID NO:2.

30. (Canceled)

31. (Currently amended) The isolated recombinant polypeptide of claim 29, wherein the immunogenic fragment comprises 20 or more contiguous amino acids of SEQ ID NO:2, wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include a co-protein carrier coupled to the polypeptide or an adjuvant, is capable of inducing an antibody that specifically binds to said fragment within SEQ ID NO:2.

32. (Previously Presented) The isolated recombinant polypeptide of claim 25, wherein the isolated recombinant polypeptide consists of SEQ ID NO:2.

33-34. (Canceled)

35. (Previously Presented) A fusion protein comprising the isolated recombinant polypeptide of claim 25.

36. - 39. (Canceled)

40. (Previously Presented) An immunogenic composition comprising the isolated recombinant polypeptide of claim 25 and a pharmaceutically acceptable carrier.

41. (Previously Presented) The immunogenic composition of claim 40, wherein the immunogenic composition further comprises at least one other *Neisseria meningitidis* antigen other than a polypeptide comprising SEQ ID NO:2.

42. (Canceled)

43. (Previously Presented) A method for inducing an antibody in a mammal comprising administering the isolated recombinant polypeptide of claim 25 to the mammal in an amount effective to induce an antibody.

44. - 49. (Canceled)

50. (Previously Presented) A fusion protein comprising the isolated recombinant polypeptide of claim 29.

51. (Previously Presented) An immunogenic composition comprising the isolated recombinant polypeptide of claim 29 and a pharmaceutically acceptable carrier.

52. - 56. (Canceled)

57. (Previously Presented) A fusion protein comprising the isolated recombinant polypeptide of claim 31.

58. (Canceled)

59. (Previously Presented) An immunogenic composition comprising the isolated recombinant polypeptide of claim 31 and a pharmaceutically acceptable carrier.

60. (Previously Presented) An immunogenic composition comprising the fusion protein of claim 35 and a pharmaceutically acceptable carrier.

61. (Canceled)

62. (Previously Presented) An immunogenic composition comprising the fusion protein of claim 50 and a pharmaceutically acceptable carrier.

63. (Previously Presented) An immunogenic composition comprising the fusion protein of claim 57 and a pharmaceutically acceptable carrier.

64. (Previously Presented) The immunogenic composition of claim 40, further comprising an adjuvant.

65. (Previously Presented) The immunogenic composition of claim 51, further comprising an adjuvant.

66. (Previously Presented) The immunogenic composition of claim 59, further comprising an adjuvant.

67. (Previously Presented) The immunogenic composition of claim 60, further comprising an adjuvant.

68. (Canceled)

69. (Previously Presented) The immunogenic composition of claim 62, further comprising an adjuvant.

70. (Previously Presented) The immunogenic composition of claim 63, further comprising an adjuvant.

71. (Currently amended) The isolated recombinant polypeptide of claim 29, wherein the polypeptide is coupled to a co-protein carrier.

72. (Currently amended) The isolated recombinant polypeptide of claim 31, wherein the polypeptide is coupled to a co-protein carrier.